Prostate cancer is a health issue we can no longer avoid. It comes as a shocker to anyone when they discover that they have cancer. However, a landmark study of the 4Kscore® test carried out by Opko Health Inc. (NASDAQ:OPK) seems to have something better to offer. The 4Kscore test aimed at detecting aggressive prostate cancer. From the study, prostate-specific antigen (PSA) screening was found to reduce prostate cancer deaths.
The study enrolled 11,506 healthy men between the ages of 45 and 73 who had no previous PSA testing. A blood sample collected from each of them was cryopreserved and were followed through December 2014 when the blood samples were tested. The study identified 317 deaths from prostate cancer while 1,223 men diagnosed with prostate cancer and another 3,028 controls.
The 4Kscore is a blood test that accurately identifies risk for aggressive prostate cancer
There have been hundreds of deaths from prostate cancer, which has become one of the biggest killers of men over 60. Apparently, a majority of those diagnosed with it do not show any physical symptoms. However, these days, a blood test is all one needs for the diagnoses and it is done through prostate-specific antigen (PSA) test. Nonetheless, some health professionals opt for a digital rectal exam.
The 4Kscore test is based on over a decade of research. It outlines the blood plasma levels of four different prostate-derived kallikrein proteins commonly known as Total PSA, Free PSA, Intact PSA and hK2. The test also adds new information to the patient-physician shared decision. All along, it has reflected reliability in decision making regarding when to perform a prostate biopsy.
Screening for prostate cancer is controversial
The Cancer Council has all along emphasized on the need for developing guidelines for PSA testing. On the other hand, many cancers require annual or bi-annual screening measures. However, choosing a treatment path is reliant on a number of factors. For example, the potential long-term side effects are to be put into consideration as well as the influence of radiation and surgery on quality of life.
All said and done, it is important to understand the consequences of each treatment. The good thing is that prostate cancer is not as aggressive as other cancers in the early stages.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.